Heng-Yen Wang1, Yajuan Qin1,2, Huiying Li3, Linda J Roman4, Pavel Martásek4,5,6, Thomas L Poulos3, Richard B Silverman1. 1. Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Northwestern University , 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States. 2. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University , Nanjing 210093, People's Republic of China. 3. Departments of Molecular Biology and Biochemistry, Pharmaceutical Sciences, and Chemistry, University of California , Irvine, California 92697-3900, United States. 4. Department of Biochemistry, University of Texas Health Science Center , San Antonio, Texas 78384-7760, United States. 5. Department of Pediatrics, First Faculty of Medicine, Charles University , 121 08 Prague, Czech Republic. 6. BIOCEV , 252 42 Vestec, Czech Republic.
Abstract
Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.
Neuronal nitric oxide synthase (n class="Gene">nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective humannNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for ratnNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against humannNOS with 1761-fold humann/e selectivity. Compound 14jalso displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.
Authors: Fengtian Xue; Jianguo Fang; Silvia L Delker; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman Journal: J Med Chem Date: 2011-03-16 Impact factor: 7.446
Authors: Subhash C Annedi; Jailall Ramnauth; Shawn P Maddaford; Paul Renton; Suman Rakhit; Gabriela Mladenova; Peter Dove; Sarah Silverman; John S Andrews; Milena D Felice; Frank Porreca Journal: J Med Chem Date: 2012-01-10 Impact factor: 7.446
Authors: Haitao Ji; Sidhartha Tan; Jotaro Igarashi; Huiying Li; Matthew Derrick; Pavel Martásek; Linda J Roman; Jeannette Vásquez-Vivar; Thomas L Poulos; Richard B Silverman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Anthony V Pensa; Maris A Cinelli; Huiying Li; Georges Chreifi; Paramita Mukherjee; Linda J Roman; Pavel Martásek; Thomas L Poulos; Richard B Silverman Journal: J Med Chem Date: 2017-08-04 Impact factor: 7.446
Authors: Ha T Do; Heng-Yen Wang; Huiying Li; Georges Chreifi; Thomas L Poulos; Richard B Silverman Journal: J Med Chem Date: 2017-11-01 Impact factor: 7.446
Authors: Dhananjayan Vasu; Huiying Li; Christine D Hardy; Thomas L Poulos; Richard B Silverman Journal: Bioorg Med Chem Date: 2022-06-11 Impact factor: 3.461